Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China.
Guangdong Provincial Key Laboratory of Virology, Institute of Medical Microbiology, Jinan University, Guangzhou, China.
Front Immunol. 2020 Dec 23;11:602256. doi: 10.3389/fimmu.2020.602256. eCollection 2020.
Coronavirus Disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a newly emerged coronavirus, and has been pandemic since March 2020 and led to many fatalities. Vaccines represent the most efficient means to control and stop the pandemic of COVID-19. However, currently there is no effective COVID-19 vaccine approved to use worldwide except for two human adenovirus vector vaccines, three inactivated vaccines, and one peptide vaccine for early or limited use in China and Russia. Safe and effective vaccines against COVID-19 are in urgent need. Researchers around the world are developing 213 COVID-19 candidate vaccines, among which 44 are in human trials. In this review, we summarize and analyze vaccine progress against SARS-CoV, Middle-East respiratory syndrome Coronavirus (MERS-CoV), and SARS-CoV-2, including inactivated vaccines, live attenuated vaccines, subunit vaccines, virus like particles, nucleic acid vaccines, and viral vector vaccines. As SARS-CoV-2, SARS-CoV, and MERS-CoV share the common genus, , this review of the major research progress will provide a reference and new insights into the COVID-19 vaccine design and development.
2019 年冠状病毒病(COVID-19)由严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)引起,该病毒是一种新出现的冠状病毒,自 2020 年 3 月以来已在全球流行,并导致许多人死亡。疫苗是控制和停止 COVID-19 大流行的最有效手段。然而,目前除了中国和俄罗斯早期或有限使用的两种人腺病毒载体疫苗、三种灭活疫苗和一种肽疫苗外,全球尚未批准使用任何有效的 COVID-19 疫苗。急需安全有效的 COVID-19 疫苗。全世界的研究人员正在开发 213 种 COVID-19 候选疫苗,其中 44 种正在进行人体试验。在这篇综述中,我们总结和分析了针对 SARS-CoV、中东呼吸综合征冠状病毒(MERS-CoV)和 SARS-CoV-2 的疫苗进展,包括灭活疫苗、减毒活疫苗、亚单位疫苗、病毒样颗粒、核酸疫苗和病毒载体疫苗。由于 SARS-CoV-2、SARS-CoV 和 MERS-CoV 属于共同的属,因此,对主要研究进展的回顾将为 COVID-19 疫苗的设计和开发提供参考和新的见解。